C57BL/6JCya-Atp1a1em1/Cya
Common Name
Atp1a1-KO
Product ID
S-KO-01159
Backgroud
C57BL/6JCya
Strain ID
KOCMP-11928-Atp1a1-B6J-VA
When using this mouse strain in a publication, please cite “Atp1a1-KO Mouse (Catalog S-KO-01159) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Atp1a1-KO
Strain ID
KOCMP-11928-Atp1a1-B6J-VA
Gene Name
Product ID
S-KO-01159
Gene Alias
Atpa-1
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 3
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000036493
NCBI RefSeq
NM_144900
Target Region
Exon 2~12
Size of Effective Region
~9.5 kb
Overview of Gene Research
ATP1A1, encoding the α1 subunit of the Na+/K+-ATPase (NKA), is a crucial gene. The heterodimeric NKA enzyme hydrolyzes ATP to establish transmembrane electrochemical gradients of Na+ and K+, which are essential for electrical signaling and cell survival. α1 is ubiquitously expressed and is the predominant paralog in peripheral axons [3,4].
In intermediate Charcot-Marie-Tooth (CMT) disease, two novel missense mutations in ATP1A1 (c.620C>T (p.S207F) and c.2629G>A (p.G877S)) were identified. These mutations led to loss of ATP1A1 protein function, downregulated its protein levels via proteasome degradation without affecting mRNA levels, thus confirming ATP1A1 as a novel causative gene for intermediate CMT [1]. In aldosterone-producing adenomas (APAs), the ATP1A1 L104R mutation stimulated cell proliferation, with higher Na/K-ATPase (NKA) expressions in ATP1A1-mutated APAs. The mutant also induced Src phosphorylation in ATP1A1-mutant cells [2]. Heterozygous Atp1a1+/- knockout mice were phenotypically normal up to 18 months, and a healthy human carrying a protein-null early truncation variant lacked clinical features of ATP1A1-related diseases, suggesting that a malfunctioning gene product is required for disease induction by ATP1A1 variants [3,4].
In summary, ATP1A1 is essential for maintaining transmembrane electrochemical gradients crucial for cell survival and electrical signaling. Studies using gene knockout models, like the Atp1a1+/- knockout mice, have provided insights into the role of ATP1A1 in diseases such as CMT and APAs, highlighting its significance in understanding the pathogenesis of these conditions.
References:
1. He, Jin, Guo, Lingling, Lin, Shan, Wang, Ning, Chen, Wanjin. 2019. ATP1A1 mutations cause intermediate Charcot-Marie-Tooth disease. In Human mutation, 40, 2334-2343. doi:10.1002/humu.23886. https://pubmed.ncbi.nlm.nih.gov/31373411/
2. Kobuke, Kazuhiro, Oki, Kenji, Gomez-Sanchez, Celso E, Hattori, Noboru, Yoneda, Masayasu. 2021. ATP1A1 Mutant in Aldosterone-Producing Adenoma Leads to Cell Proliferation. In International journal of molecular sciences, 22, . doi:10.3390/ijms222010981. https://pubmed.ncbi.nlm.nih.gov/34681640/
3. Spontarelli, Kerri, Young, Victoria C, Sweazey, Ryan, Yano, Sho T, Artigas, Pablo. 2023. ATP1A1 -linked diseases require a malfunctioning protein product from one allele. In bioRxiv : the preprint server for biology, , . doi:10.1101/2023.03.05.531165. https://pubmed.ncbi.nlm.nih.gov/37090550/
4. Spontarelli, Kerri, Young, Victoria C, Sweazey, Ryan, Yano, Sho T, Artigas, Pablo. 2023. ATP1A1-linked diseases require a malfunctioning protein product from one allele. In Biochimica et biophysica acta. Molecular cell research, 1871, 119572. doi:10.1016/j.bbamcr.2023.119572. https://pubmed.ncbi.nlm.nih.gov/37659504/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
